PCDHB2

Across TCGA pan-cancer cohorts, PCDHB2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PCDHB2 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher PCDHB2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PCDHB2 expression acts as an unfavorable survival marker.

KIRP, LIHC, and SARC are the cancer types where PCDHB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.132	0.904	<.001	36	view →
LIHC	DFS	Median	All	0.132	0.559	<.001	15	view →
SARC	DFS	Median	All	0.084	0.615	<.001	12	view →
LUAD	DFS	Median	IV	0.047	0.565	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	0.179	0.553	.022	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PCDHB2–KIRP (OS)

Open the KIRP breakdown →